SCHEMBL18880969

SCHEMBL18880969

CCCN[C@@H](C)C(=O)OC(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 2/20 0.39
SCN2A Q99250 2/20 0.39
SCN3A Q9NY46 2/20 0.39
PGR P06401 1/20 0.39
LMNA P02545 3/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
HTR1A P08908 1/20 0.37
TSHR P16473 1/20 0.36
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
PPARG P37231 1/20 0.34
NCOA2 Q15596 1/20 0.34
NCOA1 Q15788 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24134622 1.00 SCN1A (0.39) SCN1ASCN2ASCN3APGRLMNA
SCHEMBL31548591 0.85 LMNA (0.50) LMNAMAPTALOX15TSHRFAAH
SCHEMBL20222504 0.83 TSHR (0.39) LMNAGAAALOX15TSHRCHRNB2
SCHEMBL17929538 0.83 CA14 (0.45) SCN1ASCN2ASCN3APGRLMNA
SCHEMBL18162798 0.83 TSHR (0.39) LMNAGAAALOX15TSHRCHRNB2
SCHEMBL23327618 0.83 CA14 (0.45) SCN1ASCN2ASCN3APGRLMNA
SCHEMBL7904488 0.81 SCN1A (0.44) SCN1ASCN2ASCN3APGRLMNA
SCHEMBL11183460 0.81 SCN1A (0.44) SCN1ASCN2ASCN3APGRLMNA
SCHEMBL12305128 0.79 SCN1A (0.39) SCN1ASCN2ASCN3APGRLMNA
SCHEMBL2256244 0.79 LMNA (0.35) LMNAALOX15TSHRPPARGNCOA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10239911-B2 Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Atea Pharmaceuticals, Inc. (US) 2019-03-26 US disclosed
EP-2794629-B1 2',4'-DIFLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION RIBOSCIENCE LLC (US) 2017-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10239911-B2 Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment NSUN2, NUDT1, PNP SCN1A 1916/4885SCN2A 943/4885SCN3A 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.